Insider Buying: MiMedx Group, Inc. (NASDAQ:MDXG) CEO Purchases 200,000 Shares of Stock

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) CEO Joseph H. Capper acquired 200,000 shares of the company's stock in a transaction dated Friday, May 2nd. The shares were bought at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the purchase, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This represents a 60.69 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

MiMedx Group Stock Up 3.7 %

MDXG traded up $0.23 during mid-day trading on Monday, reaching $6.55. 973,945 shares of the stock were exchanged, compared to its average volume of 679,063. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a 50 day moving average price of $7.40 and a two-hundred day moving average price of $8.10. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a market capitalization of $967.74 million, a PE ratio of 11.92 and a beta of 1.85.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The firm had revenue of $88.21 million for the quarter, compared to analysts' expectations of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, research analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Institutional Investors Weigh In On MiMedx Group

Several institutional investors have recently bought and sold shares of MDXG. Invesco Ltd. raised its position in MiMedx Group by 2.2% during the 4th quarter. Invesco Ltd. now owns 56,565 shares of the company's stock valued at $544,000 after purchasing an additional 1,226 shares during the last quarter. OneDigital Investment Advisors LLC boosted its stake in MiMedx Group by 3.9% during the first quarter. OneDigital Investment Advisors LLC now owns 55,157 shares of the company's stock worth $419,000 after acquiring an additional 2,056 shares in the last quarter. Rhumbline Advisers increased its position in MiMedx Group by 1.4% during the 1st quarter. Rhumbline Advisers now owns 177,156 shares of the company's stock valued at $1,346,000 after buying an additional 2,436 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after buying an additional 2,837 shares in the last quarter. Finally, IMG Wealth Management Inc. bought a new position in MiMedx Group in the 4th quarter valued at approximately $28,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the company. StockNews.com raised MiMedx Group from a "buy" rating to a "strong-buy" rating in a report on Thursday. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.